<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Therapy</journal-id><journal-title-group><journal-title xml:lang="en">Therapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапия</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2412-4036</issn><issn publication-format="electronic">2713-1823</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">288804</article-id><article-id pub-id-type="doi">10.18565/therapy.2022.2.38-45</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">RHEUMATOID FACTOR IN GENERAL MEDICAL PRACTICE: PART I - SPECIAL FEATURES OF LABORATORY DIAGNOSTICS, DETECTABILITY AND CLINICAL SIGNIFICANCE IN RHEUMATIC DISEASES</article-title><trans-title-group xml:lang="ru"><trans-title>РЕВМАТОИДНЫЙ ФАКТОР В ОБЩЕВРАЧЕБНОЙ ПРАКТИКЕ: ЧАСТЬ I - ОСОБЕННОСТИ ЛАБОРАТОРНОЙ ДИАГНОСТИКИ, ВЫЯВЛЯЕМОСТЬ И КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ПРИ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЯХ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>LYALINA</surname><given-names>Vera V.</given-names></name><name xml:lang="ru"><surname>ЛЯЛИНА</surname><given-names>Вера Валерьевна</given-names></name></name-alternatives><bio xml:lang="en"><p>PhD, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>к.м.н., доцент кафедры госпитальной терапии им. академика Г.И. Сторожакова лечебного факультета</p></bio><email>vera_lyalina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>SKRIPNICHENKO</surname><given-names>Elina A.</given-names></name><name xml:lang="ru"><surname>СКРИПНИЧЕНКО</surname><given-names>Элина Альбертовна</given-names></name></name-alternatives><bio xml:lang="en"><p>postgraduate student of the Department of hospital therapy named after academician G.I. Storozhakov</p></bio><bio xml:lang="ru"><p>аспирант кафедры госпитальной терапии имени академика Г. И. Сторожакова лечебного факультета</p></bio><email>elkaskrip@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>BINYAKOVSKY</surname><given-names>Rostislav V.</given-names></name><name xml:lang="ru"><surname>БИНЯКОВСКИЙ</surname><given-names>Ростислав Владимирович</given-names></name></name-alternatives><bio xml:lang="en"><p>clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>binyakovskiy@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>BORISOVSKAYA</surname><given-names>Svetlana V.</given-names></name><name xml:lang="ru"><surname>БОРИСОВСКАЯ</surname><given-names>Светлана Васильевна</given-names></name></name-alternatives><bio xml:lang="en"><p>PhD., associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>к.м.н., доцент кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>svabor@inbox.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>DOLGOPOLOVA</surname><given-names>Victoria S.</given-names></name><name xml:lang="ru"><surname>ДОЛГОПОЛОВА</surname><given-names>Виктория Сергеевна</given-names></name></name-alternatives><bio xml:lang="en"><p>clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>dolgopolovavika@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>DEMURIA</surname><given-names>Tamara T.</given-names></name><name xml:lang="ru"><surname>ДЕМУРИЯ</surname><given-names>Тамара Темуриевна</given-names></name></name-alternatives><bio xml:lang="en"><p>clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>tamunademuria078@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>BABAYAN</surname><given-names>Diana V.</given-names></name><name xml:lang="ru"><surname>БАБАЯН</surname><given-names>Диана Ваграмовна</given-names></name></name-alternatives><bio xml:lang="en"><p>clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>dbabayan38@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>BOCHAROVA</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>БОЧАРОВА</surname><given-names>Анна Андреевна</given-names></name></name-alternatives><bio xml:lang="en"><p>clinical resident of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>клинический ординатор кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>bocharova.aan@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>POLYAKOVA</surname><given-names>Yulia V.</given-names></name><name xml:lang="ru"><surname>ПОЛЯКОВА</surname><given-names>Юлия Валентиновна</given-names></name></name-alternatives><bio xml:lang="en"><p>therapist of the admission Department</p></bio><bio xml:lang="ru"><p>врач-терапевт приемного отделения</p></bio><email>kirichenkoyly@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>GULSHIN</surname><given-names>Vadim A.</given-names></name><name xml:lang="ru"><surname>ГУЛЬШИН</surname><given-names>Вадим Александрович</given-names></name></name-alternatives><bio xml:lang="en"><p>therapist of the admission Department</p></bio><bio xml:lang="ru"><p>врач-терапевт приемного отделения</p></bio><email>vadimgulshin@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>MODESTOVA</surname><given-names>Anna V.</given-names></name><name xml:lang="ru"><surname>МОДЕСТОВА</surname><given-names>Анна Владимировна</given-names></name></name-alternatives><bio xml:lang="en"><p>PhD, associate professor of the Department of hospital therapy named after academician G.I. Storozhakov of the Faculty of general medicine</p></bio><bio xml:lang="ru"><p>к.м.н., доцент кафедры госпитальной терапии имени академика Г.И. Сторожакова лечебного факультета</p></bio><email>a.modestowa@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>NIKITIN</surname><given-names>Igor G.</given-names></name><name xml:lang="ru"><surname>НИКИТИН</surname><given-names>Игорь Геннадиевич</given-names></name></name-alternatives><bio xml:lang="en"><p>MD, professor, head of the Department of hospital therapy No. 2 of the Faculty of general medicine, N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Director of the National Medical Research Center «Treatment and rehabilitation center» of the Ministry of Healthcare of Russia</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зав. кафедрой госпитальной терапии № 2 лечебного факультета ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, директор ФГАУ «Национальный медицинский исследовательский центр "Лечебно-реабилитационный центр"» Минздрава России</p></bio><email>igor.nikitin.64@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">V.M. Buyanov City Clinical Hospital of the Healthcare Department of Moscow</institution></aff><aff><institution xml:lang="ru">ГБУЗ «Городская клиническая больница им. В.М. Буянова Департамента здравоохранения города Москвы»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">National Medical Research Center «Treatment and Rehabilitation Center» of the Ministry of Healthcare of Russia</institution></aff><aff><institution xml:lang="ru">ФГАУ «Национальный медицинский исследовательский центр "Лечебно-реабилитационный центр"» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2022</year></pub-date><volume>8</volume><issue>2</issue><issue-title xml:lang="en">VOL 8, NO2 (2022)</issue-title><issue-title xml:lang="ru">ТОМ 8, №2 (2022)</issue-title><fpage>38</fpage><lpage>45</lpage><history><date date-type="received" iso-8601-date="2023-02-26"><day>26</day><month>02</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, ООО «Бионика Медиа»</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2412-4036/article/view/288804">https://journals.eco-vector.com/2412-4036/article/view/288804</self-uri><abstract xml:lang="en"><p>The review presents data on the significance of rheumatoid factor (RF) in various rheumatic diseases. It has been shown that the determination of the IgM-RF level is used in clinical practice for the diagnosis of rheumatoid arthritis. At the same time, IgM-RF is a sensitive, but not sufficiently specific indicator found in serum and in other rheumatic diseases.</p></abstract><trans-abstract xml:lang="ru"><p>В предлагаемом обзоре представлены данные о значимости ревматоидного фактора (РФ) при различных ревматических заболеваниях. Продемонстрировано, что в клинической практике для диагностики ревматоидного артрита используется определение уровня IgM-РФ, который является чувствительным, но недостаточно специфичным показателем, обнаруживающимся в сыворотке и при других ревматических заболеваниях.</p></trans-abstract><kwd-group xml:lang="en"><kwd>rheumatoid factor</kwd><kwd>seropositivity</kwd><kwd>rheumatoid arthritis</kwd><kwd>articular syndrome</kwd><kwd>undifferentiated arthritis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>ревматоидный фактор</kwd><kwd>серопозитивность</kwd><kwd>ревматоидный артрит</kwd><kwd>суставной синдром</kwd><kwd>недифференцированный артрит</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Хоббс К. Лабораторные исследования. В книге: Акутота В., Арройо Р.А., Баттафарано Д.Ф. с соавт. Секреты ревматологии. Под ред. О.М. Лесняк. М.: ГЭОТАР-Медиа. 2018; с. 64-73. ISBN: 978-5-9704-4508-2.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Gualtierotti R., Ciavarella T., Meroni P.L. Rheumatoid factors. In book: Autoantibodies. 3rd edition. Ed. by Shoenfeld Y., Meroni P.L., Gershwin V.E. Amsterdam: Elsevier B.V. 2014; 751-60. ISBN: 978-0-444-56378-1. https://dx.doi.org/10.1016/C2010-0-68545-2.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ryu H.J., Takeuchi F., Kuwata S. et al. The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis. Rheumatol Int. 2011; 3(31): 315-19. https://dx.doi.org/10.1007/s00296-009-1260-5.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>de Angelis V., Meroni P.L. Rheumatoid factors. In book: Autoantibodies. 1st edition. Ed. by Peters J.B., Schoenfeld Y. Amsterdam: Elsevier Inc. 2007; pp. 755-62. ISBN: 978-0-444-52763-9.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Александрова Е.Н., Новиков А.А., Насонов Е.Л. Рекомендации по лабораторной диагностике ревматических заболеваний Общероссийской общественной организации «Ассоциация ревматологов России» - 2015. Современная ревматология. 2015; 4: 25-36. https://dx.doi.org/10.14412/1996-7012-2015-4-25-36.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Jones J.G. Biochemistry of articular disorders. In book: Marshall W., Lapsley M., Day A., Ayling R. Clinical biochemistry: Metabolic and clinical aspects. 3rd edition. London: Churchill Livingstone. 2014; pp. 636-45. ISBN: 978-0-702-05140-1.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Кишкун А.А. Клиническая лабораторная диагностика. М.: ГЭОТАР-Мелиа. 2010; с. 721-723. ISBN: 978-5-9704-1550-4.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Фридрихсберг Д.А. Курс коллоидной химии. Спб.: Химия. Ленинградское отделение. 1995; с. 41. ISBN: 5-7245-1022-7.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Жаворонок С.В., Тапальский Д.В. Иммуноферментный анализ. Учебное пособие. Гомель: Гомельский государственный медицинский университет. 2004; с. 6.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Ameratunga R., Musaad S., Sugrue C., Kyle C. Rheumatoid factor measurement-continuing problems 70 years after discovery. Clin Rheumatol. 2011; 9(30): 1215-20. https://dx.doi.org/10.1007/s10067-011-1716-3.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Devi C., Ravichandran R., Selvaraj L. et al.Comparative study of rheumatoid factor - IgM autoantibody testing by latex agglutination nephelometry and ELISA in patients with rheumatoid arthritis. Eur J Mol Clin Med. 2020. 8(7): 4521-27.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Rocha K.C., Da Fonseca Brinque L.A., Oliveira C.G.B. et al.Comparative study between immunoturbidimetric and latex agglutination methods for the detection of rheumatoid factor. J Bras Patol Med Lab. 2013; 1(49): 12-16. https://dx.doi.org/10.1590/S1676-24442013000100002.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Bas S., Perneger T.V., Kunzle E., Vischer T.L.Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors. Ann Rheum Dis. 2002; 6(61): 505-10. https://dx.doi.org/10.1136/ard.61.6.505.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Van Hoovels L., Jacobs J., Vander Cruyssen B. et al. Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis. Ann Rheum Dis. 2018; 5(77): 667-77. https://dx.doi.org/10.1136/annrheumdis-2017-212365.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Клинические рекомендации. Ревматоидный артрит. Ассоциация ревматологов России. 2018. Рубрикатор Минздрава России. Доступ: https://cr.minzdrav.gov.ru/schema/250_1 (дата обращения - 16.08.2021).</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Shmerling R.H. Rheumatoid factor: Biology and utility of measurement. 2021. URL: https://www.uptodate.com/contents/rheumatoid-factor-biology-and-utility-of-measurement (date of access - 11.02.2022).</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Westwood O.M.R., Nelson P.N., Hay F.C. Rheumatoid factors: What's new? Rheumatology (Oxford). 2006; 45(4): 379-85. https://dx.doi.org/10.1093/rheumatology/kei228.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Salzman B.E., Nevin J.E., Newman J.H. A primary care approach to the use and interpretation of common rheumatologic tests. Clin Fam Pract. 2005; 2(7): 335-58. https://dx.doi.org/10.1016/J.CFP.2005.02.009.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Taylor P., Gartemann J., Hsieh J., Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Dis. 2011; 1(1): 1-18. https://dx.doi.org/10.4061/2011/815038.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Лапин С.В., Мазинг А.В., Булгакова Т.В. с соавт. Клинические рекомендации по лабораторной диагностике аутоиммунных заболеваний. 2014. Доступ: https://medqualitypeople.ru/f/klinicheskie_rekomendacii_po_laboratornoj_diagnostike_autoimmunnyh_zabolevanij_0.pdf (дата обращения - 16.07.2021). URL: https://medqualitypeople.ru/f/klinicheskie_rekomendacii_po_laboratornoj_diagnostike_autoimmunnyh_zabolevanij_0.pdf (date of access - 16.07.2021) (In Russ.)].</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Bobbio-Pallavicini F., Alpini C., Caporali R. et al. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther. 2004; 6(3): R264-72. https://dx.doi.org/10.1186/ar1173.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>De Rycke L., Verhelst X., Kruithof E. et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2005; 2(64): 299-302. https://dx.doi.org/10.1136/ard.2004.023523.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Caramaschi P., Biasi D., Tonolli E. et al. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int. 2005; 1(26): 58-62. https://dx.doi.org/10.1007/s00296-004-0571-9.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Chen H.A., Lin K.C., Chen C.H. et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 1(65): 35-39. https://dx.doi.org/10.1136/ard.2005.038851.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Atzeni F., Sarzi-Puttini P., Dell' Acqua D. et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study. Arthritis Res Ther. 2005; 1(8): R3 https://dx.doi.org/10.1186/ar1851.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Cambridge G., Leandro M.J., Edwards J.C.W. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003; 48(8): 2146-54. https://dx.doi.org/10.1002/art.11181.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Cohen S.B., Emery P., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006; 9(54): 2793-806. https://dx.doi.org/10.1002/art.22025.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Maneiro R.J., Salgado E., Carmona L., Gomez-Reino J.J. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2013; 1(43): 9-17. https://dx.doi.org/10.1016/j.semarthrit.2012.11.007.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Faillace C., De Carvalho J.F. Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis. Rheumatol Int. 2013; 7(33): 1909-10. https://dx.doi.org/10.1007/s00296-012-2409-1.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Deane K.D., O'Donnell C.I., Hueber W. et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 2010; 11(62): 3161-72. https://dx.doi.org/10.1002/art.27638.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Deane K.D., Norris J.M., Holers V.M. Preclinical rheumatoid arthritis: Identification, evaluation, and future directions for investigation. Rheum Dis Clin North Am. 2010; 2(36): 213-41. https://dx.doi.org/10.1016/j.rdc.2010.02.001.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Федеральные клинические рекомендации по диагностике и лечению системной красной волчанки. Ассоциация ревматологов России. 2016. Доступ: https://rheumatolog.su/media/media/2018/07/18/clinrec_skv.pdf (дата обращения - 11.02.2022).</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Popescu C., Zofota S., Bojinca V., Ionescu R. The significance of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus. Rom J Intern Med. 2013; 51(3-4): 179-87.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Fedrigo A., dos Santos T.A.F.G., Nisihara R., Skare T. The lupus patient with positive rheumatoid factor. Lupus. 2018; 27(8): 1368-73. https://dx.doi.org/10.1177/0961203318759607.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Witte T., Hartung K., Sachse C. et al. Rheumatoid factors in systemic lupus erythematosus: Association with clinical and laboratory parameters. Rheumatol Int. 2000; 3(19): 107-11. https://dx.doi.org/10.1007/s002960050112.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Федеральные клинические рекомендации по диагностике и лечению болезни Шегрена. Ассоциация ревматологов России. 2016. Доступ: https://rheumatolog.su/media/media/2018/07/18/clinrec_b_shyogrena.pdf (дата обращения - 11.02.2022).</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Bournia V.K., Vlachoyiannopoulos P.G. Subgroups of Sjogren syndrome patients according to serological profiles J Autoimmun. 2012; 39(1-2): 15-26. https://dx.doi.org/10.1016/j.jaut.2012.03.001.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Wielosz E., Majdan M., Dryglewska M., Zwolak R. Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: Prevalence and relationships with joint manifestations. Adv Clin Exp Med. 2018; 27(9): 1253-57. https://dx.doi.org/10.17219/acem/69921.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Ramos-Casals M., Solans R., Rosas J. et al. Primary Sjogren syndrome in Spain: Clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008; 87(4): 210-19. https://dx.doi.org/10.1097/MD.0b013e318181e6af.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Martel C., Gondran G., Launay D. et al. Active immunological profile is associated with systemic Sjogren's syndrome. J Clin Immunol. 2011; 31(5): 840-47. https://dx.doi.org/10.1007/s10875-011-9553-3.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Fragkioudaki S., Mavragani C.P., Moutsopoulos H.M. Predicting the risk for lymphoma development in Sjogren syndrome. Medicine (Baltimore). 2016; 95(25): e3766. https://dx.doi.org/10.1097/MD.0000000000003766.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Peen E., Mellbye O.J., Haga H. IgA rheumatoid factor in primary Sjogren's syndrome. Scand J Rheumatol. 2009; 38(1): 46-49. https://dx.doi.org/10.1080/03009740802366043.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Kitagawa T., Shibasaki K., Toya S. Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjogren's syndrome. Clin Rheumatol. 2012; 31(1): 105-12. https://dx.doi.org/10.1007/s10067-011-1789-z.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Diaz-Lopez C., Geli C., Corominas H. et al. Are there clinical or serological differences between male and female patients with primary Sjogren's syndrome? J Rheumatol. 2004; 31(7): 1352-55.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Диагностика и лечение прогрессирующего системного склероза (системной склеродермии). М34.0. Ассоциация ревматологов России. 2016. Доступ: https://rheumatolog.su/media/media/2019/02/22/ssd_klin_rekomendatsii.pdf (дата обращения - 11.02.2022).</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Avouac J., Clements P.J., Khanna D. et al. Articular involvement in systemic sclerosis. Rheumatology (Oxford). 2012; 51(8): 1347-56. https://dx.doi.org/10.1093/rheumatology/kes041.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Федеральные клинические рекомендации по диагностике и лечению идиопатических воспалительных миопатий. Ассоциация ревматологов России. 2016. Доступ: https://rheumatolog.su/media/media/2018/07/18/clinrec_id_vosp_mio.pdf (дата обращения - 11.02.2022).</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Ide V., Bossuyt X., Blockmans D., De Langhe E. Prevalence and clinical correlates of rheumatoid factor and anticitrullinated protein antibodies in patients with idiopathic inflammatory myopathy. RMD Open. 2018; 4(2): e000661. https://dx.doi.org/10.1136/rmdopen-2018-000661.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Koler R.A., Montemarano A. Dermatomyositis. Am Fam Physician. 2001; 64(9): 1565-72.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Shmerling R.H., Delbanco T.L. The rheumatoid factor: An analysis of clinical utility. Am J Med. 1991; 91(5): 528-34. https://dx.doi.org/10.1016/0002-9343(91)90190-9.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Cavagna L., Nuno L., Scire C.A. et al. Serum Jo-1 autoantibody and isolated arthritis in the antisynthetase syndrome: Review of the literature and report of the experience of AENEAS Collaborative Group. Clin Rev Allergy Immunol. 2017; 52(1): 71-80. https://dx.doi.org/10.1007/s12016-016-8528-9.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Chen L., Somers A., Liu J. Antisynthetase syndrome and pleural effusion: A case report. Chest. 2020; 158(4): 1991-92. https://dx.doi.org/10.1016/j.chest.2020.08.1725.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Шаяхметова Р.У., Ананьева Л.П. Смешанное заболевание соединительной ткани. Современная ревматология. 2019; 1: 11-18. [Shayakhmetova R.U., Ananyeva L.P. Mixed connective tissue disease. Sovremennaya revmatologiya = Modern Rheumatology Journal2019; 1: 11-18 (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2019-1-11-18.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Ungprasert P., Crowson C.S., Chowdhary V.R. et al. Epidemiology of mixed connective tissue disease, 1985-2014: A population-based study. Arthritis Care Res (Hoboken). 2016; 68(12): 1843-48. https://dx.doi.org/10.1002/acr.22872.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>John K.J., Sadiq M., George T. et al. Clinical and immunological profile of mixed connective tissue disease and a comparison of four diagnostic criteria.Int J Rheumatol. 2020; 2020: 9692030. https://dx.doi.org/10.1155/2020/9692030.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Garcia-De La Torre I., Salazar-Paramo M., Salmon-De La Torre G. Mixed connective tissue disease. A clinico-serological study of 17 cases. Mol Biol Rep. 1996; 23(3-4): 153-57. https://dx.doi.org/10.1007/BF00351163.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Mimura Y., Ihn H., Jinnin M. et al. Rheumatoid factor isotypes in mixed connective tissue disease. Clin Rheumatol. 2006; 25(4): 572-74. https://dx.doi.org/10.1007/s10067-005-0185-y.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Colaris M.J.L., de Boer M., van der Hulst R.R., Cohen Tervaert J.W. Two hundreds cases of ASIA syndrome following silicone implants: a comparative study of 30 years and a review of current literature. Immunol Res. 2017; 65(1): 120-28. https://dx.doi.org/10.1007/s12026-016-8821-y.</mixed-citation></ref></ref-list></back></article>
